Distinct roles of LIF and OSM during pneumonia

LIF 和 OSM 在肺炎期间的不同作用

基本信息

  • 批准号:
    8717284
  • 负责人:
  • 金额:
    $ 6.31万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-07-01 至 2015-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Acute bacterial pneumonia is a significant source of morbidity and mortality worldwide. During pneumonia, the innate immune system rapidly detects and attacks pathogenic bacteria, while simultaneously initiating a parallel signaling system to limit collateral damage to local tissues. Our long-term goal is to develop therapeutic strategies that promote bacterial clearance while maintaining adequate tissue protection, and the first step is to better understand the signaling pathways involved. Our group has previously demonstrated that STAT3 is a key transcription factor at the center of these often-divergent outcomes, and its specific signaling depends largely on the milieu in which it is activated. The studies outlined in this proposal focus on two STAT3 activating cytokines, Leukemia Inhibitory Factor (LIF) and Oncostatin M (OSM), which appear to differentially affect these outcomes. We have previously shown that LIF is a critical cytokine involved in limiting acute lung injury during pneumonia and that LIF may be responsible for controlling a host of genes linked to cell death during bacterial pneumonia, particularly in lung epithelium. Moreover, our preliminary data suggest that LIF neutralization exacerbates pneumonia-induced epithelial apoptosis, implicating LIF-STAT3 signaling as an important countermeasure for preserving lung tissue in the setting of acute pulmonary inflammation. Significantly less is known about the role of OSM-STAT3 signaling during pneumonia. We have shown that OSM is strongly induced during pneumonia, but its physiological significance has never been explored. Our preliminary studies indicate that OSM is necessary for neutrophil recruitment and possibly neutrophil directed bacterial killing during pneumonia, suggesting that LIF and OSM, while closely related, have distinct and critical roles. Interestingly, our initial results also suggest that OSM selectively promotes expression of the neutrophil chemokine CXCL5, implicating a novel axis whereby OSM-induced CXCL5 elicits neutrophil-mediated host defense. Studies proposed in the following aims will employ complementary approaches to test our central hypothesis that the IL-6 family cytokines, LIF and OSM have crucial but distinct roles in lung protection during pneumonia: Aim 1) Test the hypothesis that LIF directly targets epithelial cells during pneumonia to limit apoptosis and acute lung injury; and Aim 2) Test the hypothesis that Oncostatin M is necessary for CXCL5- mediated neutrophil recruitment and host defense during pneumonia. Our proposal is designed to advance our understanding of STAT3 biology as it pertains to lung protection in pneumonia. Results will specifically shed light on physiological significance of LIF and OSM, which may extend to other biological principles controlling the severity of acute lung injury. Ultimately, itis our hope that a better understanding of these signaling pathways will have clinical implications in the management of bacterial pneumonia and ARDS.
描述(由申请人提供):急性细菌性肺炎是世界范围内发病率和死亡率的重要来源。在肺炎期间,先天免疫系统迅速发现并攻击致病菌,同时启动一个平行的信号系统,以限制对局部组织的附带损害。我们的长期目标是开发促进细菌清除的治疗策略,同时保持足够的组织保护,第一步是更好地了解所涉及的信号通路。我们的团队之前已经证明,STAT3是这些经常分化的结果的中心的关键转录因子,其特定的信号传导很大程度上取决于它被激活的环境。本提案中概述的研究重点是两种STAT3激活细胞因子,白血病抑制因子(LIF)和肿瘤抑制素M (OSM),它们似乎对这些结果有不同的影响。我们之前已经表明,LIF是一个关键的细胞因子,参与限制肺炎期间的急性肺损伤,并且LIF可能负责控制与细菌性肺炎期间细胞死亡相关的一系列基因,特别是在肺上皮中。此外,我们的初步数据表明,LIF中和会加剧肺炎诱导的上皮细胞凋亡,这意味着在急性肺部炎症的情况下,LIF- stat3信号是保护肺组织的重要对策。对于OSM-STAT3信号在肺炎中的作用所知甚少。我们已经证明OSM在肺炎期间被强烈诱导,但其生理意义从未被探讨过。我们的初步研究表明,在肺炎期间,OSM是中性粒细胞募集和可能的中性粒细胞定向细菌杀伤所必需的,这表明LIF和OSM虽然密切相关,但具有不同的关键作用。有趣的是,我们的初步结果还表明,OSM选择性地促进中性粒细胞趋化因子CXCL5的表达,暗示OSM诱导的CXCL5引发中性粒细胞介导的宿主防御的新轴。以下目的提出的研究将采用互补的方法来验证我们的中心假设,即IL-6家族细胞因子、LIF和OSM在肺炎期间的肺保护中具有关键但不同的作用:目的1)验证LIF在肺炎期间直接靶向上皮细胞以限制细胞凋亡和急性肺损伤的假设

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Katrina Traber其他文献

Katrina Traber的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Katrina Traber', 18)}}的其他基金

Transcriptional Regulation of Migrating Neutrophils during Pneumonia
肺炎期间迁移中性粒细胞的转录调节
  • 批准号:
    10642707
  • 财政年份:
    2021
  • 资助金额:
    $ 6.31万
  • 项目类别:
Transcriptional Regulation of Migrating Neutrophils during Pneumonia
肺炎期间迁移中性粒细胞的转录调节
  • 批准号:
    10434115
  • 财政年份:
    2021
  • 资助金额:
    $ 6.31万
  • 项目类别:
Transcriptional Regulation of Migrating Neutrophils during Pneumonia
肺炎期间迁移中性粒细胞的转录调节
  • 批准号:
    10278158
  • 财政年份:
    2021
  • 资助金额:
    $ 6.31万
  • 项目类别:
The Role of Oncostatin-M in Pneumonia
制瘤素-M 在肺炎中的作用
  • 批准号:
    9335424
  • 财政年份:
    2016
  • 资助金额:
    $ 6.31万
  • 项目类别:

相似海外基金

Combinatorial cytokine-coated macrophages for targeted immunomodulation in acute lung injury
组合细胞因子包被的巨噬细胞用于急性肺损伤的靶向免疫调节
  • 批准号:
    10648387
  • 财政年份:
    2023
  • 资助金额:
    $ 6.31万
  • 项目类别:
Lung epithelial cell-derived C3 in acute lung injury
肺上皮细胞衍生的 C3 在急性肺损伤中的作用
  • 批准号:
    10720687
  • 财政年份:
    2023
  • 资助金额:
    $ 6.31万
  • 项目类别:
Examining the role of TRMT1 and tRNA methylation in acute lung injury and ARDS
检查 TRMT1 和 tRNA 甲基化在急性肺损伤和 ARDS 中的作用
  • 批准号:
    10719249
  • 财政年份:
    2023
  • 资助金额:
    $ 6.31万
  • 项目类别:
Inducible HMGB1 antagonist for viral-induced acute lung injury.
诱导型 HMGB1 拮抗剂,用于治疗病毒引起的急性肺损伤。
  • 批准号:
    10591804
  • 财政年份:
    2023
  • 资助金额:
    $ 6.31万
  • 项目类别:
MAP2K1 AND MAP2K2 IN ACUTE LUNG INJURY AND RESOLUTION
MAP2K1 和 MAP2K2 在急性肺损伤中的作用及缓解
  • 批准号:
    10741574
  • 财政年份:
    2023
  • 资助金额:
    $ 6.31万
  • 项目类别:
Development of a new treatment for COVID-19-related acute lung injury targeting the microbiota-derived peptide corisin
针对微生物群衍生肽 corisin 开发治疗 COVID-19 相关急性肺损伤的新疗法
  • 批准号:
    23K07651
  • 财政年份:
    2023
  • 资助金额:
    $ 6.31万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Probing immunovascular mechanobiology in pneumonia-associated acute lung injury at the single capillary level
在单毛细血管水平探讨肺炎相关急性肺损伤的免疫血管力学生物学
  • 批准号:
    10679944
  • 财政年份:
    2023
  • 资助金额:
    $ 6.31万
  • 项目类别:
The amyloid precursor protein protects against acute lung injury
淀粉样前体蛋白可预防急性肺损伤
  • 批准号:
    10575258
  • 财政年份:
    2023
  • 资助金额:
    $ 6.31万
  • 项目类别:
Role of macrophages and miRNA in regulating lung macrophage polarization and lung pathogenesis during respiratory virus-induced acute lung injury in normal and diabetic Syrian hamsters.
正常和糖尿病叙利亚仓鼠呼吸道病毒引起的急性肺损伤期间巨噬细胞和 miRNA 在调节肺巨噬细胞极化和肺部发病机制中的作用。
  • 批准号:
    10701207
  • 财政年份:
    2023
  • 资助金额:
    $ 6.31万
  • 项目类别:
Identification of novel phenotypes of acute lung injury using multimodal longitudinal data
使用多模态纵向数据识别急性肺损伤的新表型
  • 批准号:
    MR/Y000404/1
  • 财政年份:
    2023
  • 资助金额:
    $ 6.31万
  • 项目类别:
    Fellowship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了